Family Communication of BRCA1/2 Results and Family Uptake of BRCA1/2 Testing in a Diverse Population of BRCA1/2 Carriers
Overview
Affiliations
Previous studies examining communication of BRCA1/2 results with relatives and family uptake of BRCA1/2 testing have sampled from predominantly white, high SES cohorts ascertained solely from tertiary care centers. No studies have focused on family communication and testing among relatives of diverse BRCA1/2 carriers. We conducted structured interviews with 73 BRCA1/2 carriers identified at a public hospital and a tertiary cancer center. We asked participants if each first- and second-degree relative was aware of their BRCA1/2 results and whether or not each relative had tested. Generalized estimating equations identified rates and predictors of family communication and testing. Participants disclosed their test results to 73 % of 606 eligible relatives and 31 % of 514 eligible relatives tested. Communication and testing rates were similar for relatives of participants from the public hospital and the tertiary cancer center. Hospital site was not a significant predictor of either result disclosure or relative uptake of testing. African American and Asian/Pacific Islander participants were significantly less likely to disclose their results to their relatives; relatives of African American participants were significantly less likely to test. Addressing these disparities will require further research into the best ways to facilitate family communication and counsel at-risk relatives of racially and socioeconomically diverse BRCA1/2 mutation carriers.
Osler T, Schoeman M, Edge J, Pretorius W, Rabe F, Mathew C Cancer Med. 2025; 14(5):e70743.
PMID: 40042150 PMC: 11881015. DOI: 10.1002/cam4.70743.
Varesco L, Di Tano F, Monducci J, Sciallero S, Turchetti D, Bighin C Fam Cancer. 2024; 24(1):9.
PMID: 39565467 DOI: 10.1007/s10689-024-00430-y.
Information needs persist after genetic counseling and testing for BRCA1/2 and Lynch Syndrome.
Peipins L, Dasari S, Viox M, Rodriguez J Breast Cancer Res Treat. 2024; 208(1):19-27.
PMID: 39046629 DOI: 10.1007/s10549-024-07377-9.
Jahani M, Ghasemi B, Soltani S, Naderi M, Nikbakht H, Hashemi S Ann Med Surg (Lond). 2024; 86(7):3945-3953.
PMID: 38989175 PMC: 11230782. DOI: 10.1097/MS9.0000000000002114.
Hodan R, Picus M, Stanclift C, Ormond K, Pichardo J, Kurian A J Community Genet. 2024; 15(4):363-374.
PMID: 38814439 PMC: 11410745. DOI: 10.1007/s12687-024-00712-z.